These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1062 related articles for article (PubMed ID: 17638395)
1. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395 [TBL] [Abstract][Full Text] [Related]
2. Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study. Barrios V; Escobar C; Calderon A; Böhm M Vasc Health Risk Manag; 2009; 5():723-9. PubMed ID: 19756164 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Volpe M; Brommer P; Haag U; Miele C Clin Drug Investig; 2009; 29(1):11-25. PubMed ID: 19067471 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. Kereiakes DJ; Neutel JM; Punzi HA; Xu J; Lipka LJ; Dubiel R Am J Cardiovasc Drugs; 2007; 7(5):361-72. PubMed ID: 17953475 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. Chrysant SG; Chavanu KJ; Xu J Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study. Fogari R; Taddei S; Holm-Bentzen M; Baszak J; Melani L; Schumacher K Clin Drug Investig; 2010; 30(9):581-97. PubMed ID: 20593911 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Volpe M; Miele C; Haag U Clin Drug Investig; 2009; 29(6):381-91. PubMed ID: 19432498 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Chrysant SG; Weber MA; Wang AC; Hinman DJ Am J Hypertens; 2004 Mar; 17(3):252-9. PubMed ID: 15001200 [TBL] [Abstract][Full Text] [Related]
9. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Oparil S; Melino M; Lee J; Fernandez V; Heyrman R Clin Ther; 2010 Jul; 32(7):1252-69. PubMed ID: 20678674 [TBL] [Abstract][Full Text] [Related]
10. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. Weir MR; Hsueh WA; Nesbitt SD; Littlejohn TJ; Graff A; Shojaee A; Waverczak WF; Qian C; Jones CJ; Neutel JM J Clin Hypertens (Greenwich); 2011 Jun; 13(6):404-12. PubMed ID: 21649839 [TBL] [Abstract][Full Text] [Related]
11. Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Greathouse M Vasc Health Risk Manag; 2006; 2(4):401-9. PubMed ID: 17323594 [TBL] [Abstract][Full Text] [Related]
12. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. Mallion JM; Heagerty A; Laeis P J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562 [TBL] [Abstract][Full Text] [Related]
13. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. Shimada K; Ogihara T; Saruta T; Kuramoto K; Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495 [TBL] [Abstract][Full Text] [Related]
14. Olmesartan medoxomil evaluated for safety and efficacy in Indian patients with essential hypertension: a real world observational postmarketing surveillance. Rana R; Singh A J Assoc Physicians India; 2010 Feb; 58():77-83. PubMed ID: 20653147 [TBL] [Abstract][Full Text] [Related]
15. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Barrios V; Brommer P; Haag U; Calderón A; Escobar C Clin Drug Investig; 2009; 29(7):427-439. PubMed ID: 19499960 [TBL] [Abstract][Full Text] [Related]
16. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis. Malacco E; Omboni S; Mallion JM; Volpe M; High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):213-22. PubMed ID: 23430666 [TBL] [Abstract][Full Text] [Related]
17. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials. Heagerty AM; Mallion JM Drugs Aging; 2009; 26(1):61-76. PubMed ID: 19102515 [TBL] [Abstract][Full Text] [Related]
18. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study. Kereiakes DJ; Maa JF; Shojaee A; Dubiel R Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306 [TBL] [Abstract][Full Text] [Related]
20. Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open label sub-study in German patients. Böhm M; Ewald S; Curr Med Res Opin; 2006 Jul; 22(7):1375-80. PubMed ID: 16834836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]